# A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Study · id `cardio:ct-nct07023614` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07023614](<https://clinicaltrials.gov/study/NCT07023614>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07023614

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 165 participants.

## Technical summary

Registry record NCT07023614. Randomized; triple masking; primary purpose treatment. Start 2025-10-06 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 165 participants (planned count; ClinicalTrials.gov record NCT07023614, source copy `cardio:ctgov-nct07023614-2026-10-26`, retrieved 2026-10-31)
- Started: 2025-10-06 (actual) (ClinicalTrials.gov record NCT07023614, source copy `cardio:ctgov-nct07023614-2026-10-26`, retrieved 2026-10-31)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07023614, source copy `cardio:ctgov-nct07023614-2026-10-26`, retrieved 2026-10-31)
- Completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT07023614, source copy `cardio:ctgov-nct07023614-2026-10-26`, retrieved 2026-10-31)
- Countries: United States; Austria; Belgium; France; Germany; Italy; Netherlands; Poland; Portugal; Spain; United Kingdom (ClinicalTrials.gov record NCT07023614, source copy `cardio:ctgov-nct07023614-2026-10-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07023614-2026-10-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
- Acronym: FORTITUDE-HCM
- Condition: Non-obstructive Hypertrophic Cardiomyopathy
- Intervention (Drug): Ninerafaxstat 200mg MR
- Intervention (Drug): Placebo
- Lead sponsor: Imbria Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)

## Provenance

Content hash: 76d3aa8311515692b73c0e8a38f654437f4b645ee1a1559d16af9f00f7e4b72d
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
